Alfred Corey

Suggest Changes
Learn More
PURPOSE To assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of mapatumumab (HGS-ETR1, TRM-1), a fully human agonist monoclonal antibody directed to the tumor(More)
2515 Background: HGS-ETR1 (mapatumumab) is a fully-human monoclonal antibody agonistic to the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1, DR4). Activation of(More)
2533 Background: TRAIL is a member of the TNF ligand superfamily. There is strong evidence for its ability to induce apoptosis in cancer cell lines. TRAIL causes apoptosis via 2 death receptors [DR4(More)